EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study

Akkumulierte Sicherheitsdaten der Therapie mit rekombinantem humanem Wachstumshormon bei koreanischen Kindern über 10 Jahre: Zwischenanalyse der LG Growth Study

Yoo-Mi Kim iD, Young-Jun Rhie, Hyun-Wook Chae, Jaehyun Kim iD, Young Ah Lee, Hae Sang Lee, Yong Hee Hong, Ja Hye Kim, Moon Bae Ahn, Yejin Jeon, Choong Ho Shin iD

Endocrine Connections · 01.06.2026 · 15 (6)

DOI: 10.1530/ec-26-0073 ↗

Auf einen Blick

In einer prospektiven Registerstudie mit 5.040 Kindern trat unter rhGH selten eine Arzneimittelreaktion auf. Malignome und Tumorrezidive lagen im Bereich internationaler Registerdaten.

Fragestellung

Wie sicher ist rhGH bei koreanischen pädiatrischen Patient:innen mit Wachstumsstörungen im Langzeitverlauf?

Methode

Prospektive, multizentrische Beobachtungsstudie aus dem landesweiten LG Growth Study-Register; Analyse von November 2011 bis Dezember 2022.

Ergebnisse

5.040 Patient:innen aus 96 Zentren, 19.878 Patient-years. AEs 34,2 %, ADRs 7,0 %, SAEs 3,2 %, SADRs 0,3 %. SIR für maligne Neoplasien 1,1 (95 %-KI 0,21–2,69).

Einschränkungen

Follow-up nur während aktiver GH-Therapie; Dauer daher patient:innenabhängig. Zwischenanalyse.

Schlussfolgerung der Autor:innen

Die rhGH-Therapie zeigte über 10 Jahre eine niedrige Inzidenz von ADRs und SADRs; Malignome und Tumorrezidive entsprachen globalen Registern. Eine weitere Überwachung bleibt erforderlich.

Kernaussagen

  • AEs bei 34,2 % der Patient:innen, ADRs bei 7,0 %
  • SADRs traten bei 0,3 % auf
  • SIR für Malignome 1,1 (95 %-KI 0,21–2,69)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 18.05.2026. Verfasst von Yoo-Mi Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Chungnam National University Sejong Hospital, College of Medicine, Chungnam National University, Sejong, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to evaluate the long-term safety outcomes of recombinant human growth hormone (rhGH) administered to Korean pediatric patients with growth disorders, including growth hormone deficiency, Turner syndrome, idiopathic short stature, small for gestational age, chronic kidney disease, and Prader–Willi syndrome, using the 10-year interim data from the nationwide LG Growth Study registry in the Republic of Korea.

Design

This is a prospective, multicenter, observational study.

Methods

This interim analysis included 5,040 patients from 96 centers, representing 19,878 patient-years of treatment between November 2011 and December 2022. Although the registry spans 10 years, follow-up was limited to periods of active GH treatment and, therefore, varied across patients. Patients received daily or weekly rhGH. Adverse events (AEs), adverse drug reactions (ADRs), serious AEs (SAEs), and serious ADRs (SADRs) were recorded and compared with international registry data.

Results

Overall, AEs occurred in 34.2% of patients, ADRs in 7.0%, SAEs in 3.2%, and SADRs in 0.3%. The most frequent AE was scoliosis (1.6%), followed by headache (0.8%) and injection site pain (0.5%). Three malignant neoplasms were reported, yielding a standardized incidence ratio of 1.1 (95% confidence interval: 0.21–2.69), comparable to expected national rates. Craniopharyngioma recurrence occurred in 14.3% of affected patients, consistent with international data.

Conclusion

Over the 10 years, rhGH therapy in Korean pediatric patients demonstrated a low incidence of ADRs and SADRs, with malignancy and tumor recurrence rates similar to those in global registries. These findings support the long-term safety of rhGH for pediatric growth disorders, with continued surveillance warranted. Significance Using 10 years of real-world data from a pediatric registry, conducted in the Republic of Korea, this study provides one of the largest single-nation safety evaluations of rhGH therapy across multiple etiologies of short stature. The low incidence rates of ADRs and SADRs, in alignment with rates reported for other large-scale international registries, provide reassuring evidence of the safety of rhGH for clinicians and caregivers.

Schlagwörter

Stichwörter der Autor:innen

growth hormonemanagement of endocrine diseasepediatric endocrinologytreatment of endocrine disease

Autor:innen und Institutionen

  • Department of Pediatrics, Chungnam National University Sejong Hospital, College of Medicine, Chungnam National University, Sejong, Republic of Korea.
  • Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Republic of Korea.

ORCID-Profile: Yoo-Mi Kim, Jaehyun Kim, Choong Ho Shin

Zitieren

APA

Kim, Y. M., Rhie, Y. J., Chae, H. W., Kim, J., Lee, Y. A., Lee, H. S., Hong, Y. H., Kim, J. H., Ahn, M. B., Jeon, Y., & Shin, C. H. (2026). Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study. Endocrine Connections, 15(6). https://doi.org/10.1530/ec-26-0073

Vancouver

Kim YM, Rhie YJ, Chae HW, Kim J, Lee YA, Lee HS, et al. Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study. Endocrine Connections. 2026;15(6). doi:10.1530/ec-26-0073

BibTeX
@article{Kim2026,
  author = {Kim, Yoo-Mi and Rhie, Young-Jun and Chae, Hyun-Wook and Kim, Jaehyun and Lee, Young Ah and Lee, Hae Sang and Hong, Yong Hee and Kim, Ja Hye and Ahn, Moon Bae and Jeon, Yejin and Shin, Choong Ho},
  title = {Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study},
  journal = {Endocrine Connections},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1530/ec-26-0073}
}
Kostenlos starten →